Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Tamayo Louis Edward, holds the title of Chief Financial Officer at Lexeo Therapeutics, Inc..
On 2026-11-17, the insider transacted 1,007 shares.The shares were transacted at a weighted average price of $3.26 per share, resulting in a total market-relevant value of $3K.
Tamayo Louis Edward (Chief Financial Officer) sold $3K of $LXEO
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.